RxDoctor Payments Data

Laurie Marinaro-Pascale

Acute Care · Flemington, NJNPI 1598859936

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,387 of the $6,418 with a category attached, or 68.4%. 33 manufacturers reported payments, led by Medtronic at 58.1% of the total. Reporting peaked in 2023 at $3,224 and has fallen 74.9% since, to $808 in 2025. Among acute care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,418in general payments, 2019–2025

Across 168 payments — averaging $38.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Atricure, Inc.$379
  • Boston Scientific$317
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$298
  • Amgen$252
  • E.r. Squibb & Sons, L.L.C.$152
  • plus $1K from 27 others

What the payments were for

  • Travel & lodging$2,03132%
  • Food & beverage$4,38768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,418 in reported general payments places this provider in the 95th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$137,678
XareltoRivaroxaban52$58,701
EntrestoSacubitril/Valsartan19$15,403
Metoprolol Succinate224$4,086
Dofetilide19$2,894
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$1,752
Midodrine Hcl33$1,586
Flecainide Acetate28$1,267
Diltiazem 24hr ErDiltiazem Hcl39$962
Rosuvastatin Calcium47$917
Atorvastatin Calcium88$897
Amiodarone Hcl47$881
Amlodipine Besylate113$844
Carvedilol63$761
Diltiazem 24hr Er (La)Diltiazem Hcl15$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$137,678130 claims
Johnson & JohnsonXarelto$146$58,70152 claims
NovartisEntresto$128$15,40319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 656 acute care providers in New Jersey.

Other acute care in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →